BIOMÉRIEUXETEST® APPLICATION GUIDE (EAG)

16273D - en - 2019/11

AEROBESORGANISM

SPECIFIC
PHENOTYPEINOCULUM
MEDIA 6)
McF equivalent
Mueller Hinton agar
(MHA)

0.5

Suspension
mediumSaline

INCUBATIONSUGGESTED MIC PANEL 3)
Time (h)Cefoxitin (FX)

18-24hTemperature/
Atmosphere
35 ± 2°C
Ambient air

RECOMMENDEDQUALITY CONTROL
StrainStaphylococcus
aureusS. aureus

29213TM≤ 4 mg/L

43300TM> 4 mg/L

MHA + 2% NaCl

0.5-1

SalineOxacillin (OX)
Amoxicillin/clavulanic acid (XL)

24h

35 ± 2°C
Ambient air

S. aureus

43300TM- Phenotype interpretation:
OX  4 µg/mL and
XL  8 µg/mL- Heavier inoculum
improves detection of lowlevel R

MHA + 2% NaCl

0.5-1

SalineOxacillin (OX)
Amoxicillin/clavulanic acid (XL)

24h

35 ± 2°C
Ambient air

S. aureus

29213TM- Phenotype interpretation:
OX  4 µg/mL and
XL ≤ 4 µg/mL

48h

35 ± 2°C
Ambient air

43300TM- Phenotype interpretation:
OX  0.5 µg/mL- Heavier inoculum
improves detection of lowlevel R

MRSA

BORSA

MRCNS

MHA + 2% NaCl

0.5-1

SalineOxacillin (OX)

Staphylococci

VISA/hVISA 1) Brain Heart Infusion agar
2
(macromethod) (BHI agar) 1)

VISA/hVISACOMMENTS 4)

ATCC®

MHA + 5% blood
MHF (Mueller Hinton +5% horse blood +20mg/L βNAD)(EUCAST)

0.5

S. aureus

Vancomycin (VA)
Teicoplanin (TP) 1)

24h.
Confirm at
48h

35 ± 2°C
Ambient air

S. aureus
QC ranges:
TP = 0.5-2 µg/mL
VA = 1-4 µg/mL

29213TM- 0.1 mL inoculum/ 90mm
plate
- Phenotype interpretation:
VA  8µg/mL andTP  8µg/mL,OR
TP 12 µg/mL (alone)= VISA/hVISA- Confirm VISA/hVISA by
PAP

Mueller Hinton
ETEST® GRD2) (Vancomycin (VA) /broth
Teicoplanin (TP) 1))(MH broth)18-24h.
Confirm at
48h

35 ± 2°C
Ambient air

S. aureus
S. aureus
S. aureus

29213TM
700698TM
700699TM- Confirm VISA/hVISA by
PAP

BHI brothbioMérieux SA

English - 1

ETEST® Application Guide (EAG)ORGANISM

16273D - en - 2019/11

INOCULUM

SPECIFIC
PHENOTYPEVISA/VRSA(standard
method)MRSA
Secondary
panel

MEDIA

6)

McF equivalent

MHA

MHA

0.5

0.5

Suspension
medium

MHA

MHA

0.5

0.5

SUGGESTED MIC PANEL

Time (h)Temperature/
Atmosphere

RECOMMENDEDQUALITY CONTROL
Strain35 ± 2°C
Ambient air

S. aureus

29213

TM

Vancomycin (VA)

24h

SalineClindamycin (CM)Daptomycin (DPC)
Linezolid (LZ)
Vancomycin (VA)
Teicoplanin (TP) 1)
Quinupristin/dalfopristin (QDA)
Rifampicin (RI) 1)

16-20h.
35 ± 2°C
VA and TP fullAmbient air
24h

S. aureus

29213TM

SalineBenzylpenicillin (PG)
Erythromycin (EM)Linezolid (LZ)
Trimethoprim/sulfamethoxazole (TS)Vancomycin (VA)
Teicoplanin (TP) 1)
Ciprofloxacin (CI)

16-20h.
35 ± 2°C
VA and TP fullAmbient air
24h

S. aureus

29213TM

SalineAmpicillin (AM)
Daptomycin (DPC)
Linezolid (LZ)
Quinupristin/dalfopristin (QDA)
Vancomycin (VA)
Teicoplanin (TP) 1)
Minocycline (MC)16-20h.
TP at 24h.
VA at 24h
35 ± 2°C
or even 48h Ambient air(see
COMMENTS)

E. faecalis

HLAR

MHA

0.5-1

Saline

Gentamicin (GM) high range
Streptomycin (SM) high range 1)

bioMérieux SA

English - 2

24h.
35 ± 2°C
Confirm SM at
Ambient air
48h- Phenotype interpretation:
VA  4µg/mL = VISA
VA  16µg/mL = VRSA
(CLSI)

29212TM- For Enteroccocus
faecium only, extend the
incubation time to48 hours when the VA
MIC is 3 or 4 µg/mL after
24 hours.

29212TM- Heavier inoculum
preferable- SM > 1024 µg/mL or
GM > 512 µg/mL =positive HLAR (CLSI)- SM > 512 µg/mL or
GM > 128 µg/mL =positive HLAR (EUCAST)Enterococci
E. faecalis
QC ranges:
GM = 4-16 µg/mL
SM = 64–256 µg/mL

COMMENTS 4)

ATCC®

SalineStaphylococci
Non-MRSA
secondarypanel

INCUBATION
3)

ETEST® Application Guide (EAG)ORGANISM

16273D - en - 2019/11

INOCULUM

SPECIFIC
PHENOTYPE

MEDIA

6)

McF equivalent

MHA

Suspension
mediumMHA

MBL MP/MPI 1) MHA

SUGGESTED MIC PANEL

Time (h)Saline

Gentamicin (GM)
Piperacillin/ tazobactam (PTc)
Cefepime (PM)Ciprofloxacin (CI)
Imipenem (IP)Aztreonam (AT)

0.5
(1 for mucoidorganisms)

Saline0.5(1 for mucoidorganisms)

Saline0.5(1 for mucoidorganisms)

Enterobacteriaceae

ESBL

INCUBATION
3)

Temperature/
Atmosphere

MHA

0.5

MHA

0.5
(1 for mucoidorganisms)

Escherichia coli
E. coliCefotaxime/cefotaxime + clavulanic
acid (CT/CTL)
Ceftazidime/ceftazidime + clavulanic
16-20hacid (TZ/TZL)
Cefepime/cefepime + clavulanic acid
(PM/PML) 1)

35218TM
700603TM

35 ± 2°C
Ambient air

E. coli
Klebsiellapneumoniae(ESBL positive)
Pseudomonas
aeruginosa

Meropenem/Meropenem +EDTA(MP/MPI)

35 ± 2°C
Ambient air

K. pneumoniae
K. pneumoniae

700603TM- Investigate ND results by
BAA-2146TM
an alternative method
700603TM

35 ± 2°C
Ambient air

Klebsiellapneumoniae(negative)
K. pneumoniae(positive)

27853TM35218TM(PTc)

16-20h.

MHA

0.5(1 for mucoidorganisms)

MBL IP/IPI

MHA

0.5
(1 for mucoidorganisms)

MHA

0.5
(1 for mucoidorganisms)

MBL IP/IPI- Investigate ND results byan alternative method27853TM

16-20hSalineCeftazidime (TZ)
Gentamicin (GM)Aztreonam (AT)
Ciprofloxacin (CI)
Imipenem (IP)Piperacillin/tazobactam (PTc)

16-20h.
48h for slow
growers

35 ± 2°C
Ambient air

P. aeruginosaE. coli

Saline16-20h.
Imipenem/imipenem + EDTA (IP/IPI) 48h for slow
growers

35 ± 2°C
Ambient air

P. aeruginosa
27853TM(negative)
Stenotrophomonas
13636TM
maltophilia (positive)

SalineCeftazidime (TZ)
Meropenem (MP)Amikacin (AK)Ampicillin/sulbactam (AB)Levofloxacin (LE)
Minocycline (MC)20-24h.
48h for slow
growers

35 ± 2°C
Ambient air

P. aeruginosaE. coli

Saline16-20h.
Imipenem/imipenem + EDTA (IP/IPI) 48h for slow
growers

35 ± 2°C
Ambient air

P. aeruginosa
27853TM(negative)
Stenotrophomonas
13636TM
maltophilia (positive)

Acinetobacter spp.

1)25922TM35218TM (PTc)

Cefotetan/Cefotetan + Cloxacillin(CN/CNI)

SalinePseudomonas spp.

1)

StrainCOMMENTS 4)

ATCC®

35 ± 2°C
Ambient air

16-20hEnterobacteriaceae
AmpC 2)RECOMMENDEDQUALITY CONTROL

bioMérieux SA

English - 3

BAA-1144TM- Investigate ND results byan alternative method- Investigate ND results byan alternative method27853TM35218TM (AB)- Investigate ND results byan alternative method

ETEST® Application Guide (EAG)ORGANISM

Burkholderia cepacia

Stenotrophomonas
maltophilia

16273D - en - 2019/11

INOCULUM

SPECIFIC
PHENOTYPE

MEDIA

6)

McF equivalent

MHA

0.5
(1 for mucoidorganisms)

MHA

0.5
(1 for mucoidorganisms)

Suspension
mediumRECOMMENDEDQUALITY CONTROLINCUBATIONSUGGESTED MIC PANEL

3)Time (h)Temperature/
Atmosphere

SalineTrimethoprim/sulfamethoxazole (TS)
Ceftazidime (TZ)
Levofloxacin (LE)Meropenem (MP)Minocycline (MC)20-24h.
48h for slow
growers

35 ± 2°C
Ambient air

E. coli

25922TM

SalineTrimethoprim/sulfamethoxazole (TS)
Ceftazidime (TZ)
Levofloxacin (LE)
Minocycline (MC)Ticarcillin/clavulanic acid (TLc)

20-24h.
48h for slow
growers

35 ± 2°C
Ambient air

E. coliE. coli

25922TM35218TM (TLc)

bioMérieux SA

English - 4

StrainATCC®

COMMENTS 4)

ETEST® Application Guide (EAG)

16273D - en - 2019/11

FASTIDIOUS ORGANISMS
ORGANISM

Pneumococci

SPECIFIC
PHENOTYPEINOCULUM
MEDIA

6)

McF equivalent

MHA + 5% blood(CLSI)MHF (EUCAST)

0.5(1 for mucoidorganisms)

SUGGESTED MIC PANEL

Time (h)35 ± 2°C
5% CO2

Streptococcus
pneumoniae

49619TMMH broth or
BHI broth

Benzylpenicillin (PG)
Cefotaxime (CT)
Chloramphenicol (CL)
Ofloxacin (OF)Linezolid (LZ) 1)
Vancomycin (VA)
Daptomycin (DPC)

20-24h35 ± 2°C
5% CO2

S. pneumoniae

49619TM

20-24h35 ± 2°C
5% CO25)5)35 ± 2°C
5% CO2

Haemophilus
influenzae
H. influenzae

49247TM

20-24h5)5)

MH chocolate agar +0.001% pyridoxal HCl + 1
0.01% cysteineBroth(MH broth or
BHI broth)Haemophilus
influenzae

Haemophilus TestMedia (HTM) (CLSI)MHF (EUCAST)

0.5(1 for mucoidorganisms)

MH broth or
HTM broth(or BHI broth)

MHA + 5% blood(CLSI)MHF (EUCAST)

0.5

MH broth or
BHI broth1

Metronidazole (MZ)
Brucella broth Clindamycin (CM)or MH brothCefoxitin (FX)(or Schaedler Imipenem (IP)Broth + vit K3) Piperacillin/tazobactam (PTc)
Benzylpenicillin (PG)

Anaerobes

Strain20-24hAbiotrophia &Granulicatella spp. 1)

Amoxicillin/ clavulanic acid (XL)
Cefotaxime (CT)
Meropenem (MP)Trimethoprim/sulfamethoxazole (TS)
Chloramphenicol (CL)20-24hbioMérieux SA

English - 5

35 ± 2°C
5% CO224-72h(48h for CM). 35 ± 2°C
Confirm all
Anaerobic
S results at
system48h.

COMMENTS 4)

ATCC®

MH broth or
BHI broth

MHA + 5% blood(CLSI)MHF (EUCAST)

Brucella agar +5% blood +vitamin K (1 µg/mL) +hemin (5 µg/mL) (BBA)(CLSI)

Temperature/
Atmosphere

Meropenem (MP)Cefotaxime (CT)Benzylpenicillin (PG)
Clindamycin (CM) 1)
Vancomycin (VA)
Trimethoprim/sulfamethoxazole (TS)Streptococci

Moraxella catarrhalis 1)

0.5(1 for mucoidorganisms)

Suspension
mediumRECOMMENDEDQUALITY CONTROLINCUBATION
3)

49766TM(MP, XM)

Bacteroides fragilis 25285TM
B. thetaiotaomicron 29741TM
Eubacterium lentum 43055TM- For obligate anaerobes,
ensure anaerobic
conditions aremaintained throughout
processing- DO NOT VORTEX- Anaerobiosis must be
achieved within
1-2 hours for MZETEST® Application Guide (EAG)

SPECIFIC
PHENOTYPE

ORGANISM

16273D - en - 2019/11

INOCULUM
MEDIA

6)

McF equivalent

Helicobacter pylori 1)

MHA + 5% blood( 2 weeks old) (CLSI)

Gonococci

Supplemented GC agar
(CLSI)
0.5
MH chocolate agar

Meningococci 1)

MHA + 5% blood(CLSI)MH chocolate agar

Campylobacter spp.

1)

MHA + 5% blood(CLSI)MHF (EUCAST)

3

0.5

1

Suspension
mediumINCUBATIONSUGGESTED MIC PANEL

3)Time (h)Temperature/
Atmosphere

Helicobacter pylori

43504TM35 ± 2°C
5% CO2

Neisseriagonorrhoeae

49226TM- 3-4 strips max./150mm
plate to facilitate reading

35 ± 2°C
5% CO2

S. pneumoniae
E. coli

49619TM
25922TM- Work in BSC

33560TM- 3-4 strips max./150mm
plate to facilitate reading- Do not invert plate- Campylobacter colonies
may be translucent anddifficult to see.
Tilt plate and use
oblique light to read
endpoint.

MH broth +5% serumor BHI broth +5% serumAmoxicillin (AC)Clarithromycin (CH)
Metronidazole (MZ)
Tetracycline (TC)MH broth(or BHI broth)

Ciprofloxacin (CI)
Benzylpenicillin (PG)
Tetracycline (TC)
Ceftriaxone (TX)
Spectinomycin (SC) 1)

20-24hBroth(BHI broth)

Ciprofloxacin (CI)
Benzylpenicillin (PG)
Trimethoprim/sulfamethoxazole (TS)Meropenem (MP)
Ceftriaxone (TX)

24h

Ciprofloxacin (CI)
Gentamicin (GM)
Erythromycin (EM)Doxycycline (DC)bioMérieux SA

48-72hEnglish - 6

StrainCOMMENTS 4)

ATCC®
- 1 strip/90mm plate- Strip handle to beplaced at edge of plate.
- H. pylori colonies are
pin-point, translucent
and difficult to see.
Tilt plate and use
oblique light to read
endpoint.

35 ± 2°C
Microaerophilic,
72h or longer
except MZ first 24hanaerobic

Broth(BHI broth)

RECOMMENDEDQUALITY CONTROL

35 ± 2°C
Microaerophilic

Campylobacter
jejuniETEST® Application Guide (EAG)

16273D - en - 2019/11

FASTIDIOUS GRAM-POSITIVE ORGANISMS 1)
ORGANISM

Arcanobacterium spp.,
Listeria
monocytogenes*,
Erysipelothrix,
Lactobacillus,
Corynebacterium,
Bacillus spp.,
Rothia,Pediococcus*,
Leuconostoc*, andGemella spp.*

SPECIFIC
PHENOTYPEINOCULUM
MEDIA

6)MHA + 5% blood(CLSI)* MHF (EUCAST)McF equivalent

Suspension
medium1

Broth(BHI broth)

RECOMMENDEDQUALITY CONTROLINCUBATIONSUGGESTED MIC PANEL

3)Time (h)Temperature/
Atmosphere20-24h (48h if 35 ± 2°C
required)
5% CO2

bioMérieux SA

English - 7

ATCC®

Strain5)

5)

COMMENTS 4)

ETEST® Application Guide (EAG)

16273D - en - 2019/11

FASTIDIOUS GRAM-NEGATIVE ORGANISMS 1)
ORGANISM

SPECIFIC
PHENOTYPEINOCULUM
MEDIA

6)

McF equivalent

Suspension
mediumRECOMMENDEDQUALITY CONTROLINCUBATIONSUGGESTED MIC PANEL

3)Time (h)Temperature/
Atmosphere

StrainBartonella spp.

MH chocolate agar

1

Broth
(BHI broth)3-5 days

35 ± 2°C
5% CO25)

5)

Bordetella pertussis

Regan-Lowe
Bordet-Jengou
or MHA + 5% blood

3

Broth
(BHI broth)3-5 days

35 ± 2°C
Ambient air
in bags,
moist

5)

5)

Capnocytophaga spp.

Brucella agar +5% blood +vitamin K (1 µg/mL) +hemin (5 µg/mL) (BBA)

1

Broth
(BHI broth)48h

35 ± 2°C
5% CO25)

5)

Legionella spp.

Buffered Charcoal
Yeast Extract (BCYE)

1

Broth
(BHI broth)3-5 days

35 ± 2°C
5% CO2

5)

5)

Pasteurella spp.

MHA + 5% blood(CLSI)MHF (EUCAST)

1

Broth
(BHI broth)48h

35 ± 2°C
5% CO2

5)

5)

Francisella tularensis

Cysteine Heart Agar +10% blood 1) (or +2% haemoglobin 3))
alternatively, Glucose
Cysteine Blood Agar

1

Suspend 48hcolonies fromchocolateagar in broth(BHI broth)

Clindamycin (CM)
Tetracycline (TC)
Ciprofloxacin (CI)
Gentamicin (GM)48-72h37 ± 2°C
5% CO2

5)

5)

HACEK group

MHA +1% haemoglobin +1% IsoVitalex
or HTM
or BBA

1

Broth(BHI broth)

Levofloxacin (LE)
Imipenem (IP)Trimethoprim/sulfamethoxazole (TS)
Ceftriaxone (TX)

24-72h35 ± 2°C
5% CO2

H. influenzae
H. influenzae

49247TM
49766TM (IP)bioMérieux SA

English - 8

COMMENTS 4)

ATCC®

- Testing should only be
performed in appropriate
reference laboratories.
- Perform all work within
BSC Class IIA andminimum BSL 2
environment.

ETEST® Application Guide (EAG)

16273D - en - 2019/11

MYCOBACTERIA AND AEROBIC ACTINOMYCETES 1)
ORGANISM

Mycobacterium
tuberculosis

SPECIFIC
PHENOTYPEINOCULUM
MEDIA

6)

Middlebrook 7H11 +10% OADC agar

INCUBATIONSUGGESTED MIC PANEL

McF equivalent

Suspension
medium3-4

M7H9 broth +0.5% tween +2% glycerol
Vortex withsterile glass
beads
3-5 mins,
settle 20 mins
& adjust
supernatant
to correct
turbidity.

Ethambutol (EB)
Ethionamide (ET)Isoniazide (IZ)
Rifampicin (RI)3)

Time (h)Temperature/
Atmosphere

RECOMMENEDQUALITY CONTROL
Strain5-10 days

37 ± 2°C
5-10% CO2

Mycobacterium
tuberculosis
M. tuberculosis- Pre-incubation 24h- 1 strip/90mm plate, seal
plates
AW388- Perform all work within®)
BSC class IIA(not ATCC

Amikacin (AK)Ciprofloxacin (CI)Clarithromycin (CH)
Rifampicin (RI)

5-10 days

35 ± 2°C(M. marinumat 30°C)
5% CO2

M. avium
M. avium spp. avium
M. marinum
M. kansasii

700898TM
35713TM
927TM
12478TM- 1 strip/90mm plate, seal
plates- Antibiogram is species
specific- Subculture twice before
preparing inoculum- 3-4 strips max./150mm
plate to facilitate reading

27294TM

Nontuberculous
mycobacteria

MHA + 10% OADC +5% blood(M. kansasii use same
agar as for MTB)

1
(3 for
M. kansasii)

M7H9 brothVortex withsterile glass
beads
3-5 mins,
settle 20 mins
& adjust
supernatant
to correct
turbidity.

Rapid growing
mycobacteria

MHA + 5% blood

1

SalineCefoxitin (FX)
Imipenem (IP)Ciprofloxacin (CI)Clarithromycin (CH)48-72h30-35°C
Ambient air,moist

M. fortuitum
M. peregrinum

6841TM
700686TM

1

Broth(BHI broth)

Amikacin (AK)Trimethoprim/sulfamethoxazole (TS)Ciprofloxacin (CI)Clarithromycin (CH)
Imipenem (IP)48-72h(dependent
on spp.)35 ± 2°C
Ambient air

S. aureus

29213TM

Nocardia spp.

MHA + 5% blood

COMMENTS 4)

ATCC®

bioMérieux SA

English - 9

ETEST® Application Guide (EAG)

16273D - en - 2019/11

FUNGI
ORGANISM

SPECIFIC
PHENOTYPEINOCULUM
MEDIA

6)

McF equivalent

Suspension
mediumYeast

RPMI 1640 +2% glucose +MOPS +
1.5% Bacto agar

0.5
(1 forCryptococcus
neoformans)

Mould

RPMI 1640 +2% glucose +MOPS +
1.5% Bacto agar

0.5 Aspergillus
spp.
Saline +(1 for Fusarium, Tween 20
Rhizopus spp.)

1)

Saline

INCUBATIONSUGGESTED MIC PANEL

3)Time (h)Temperature/
Atmosphere

RECOMMENDEDQUALITY CONTROL
StrainCOMMENTS 4)

ATCC®

Fluconazole (FL)
Itraconazole (IT)Amphotericin B (AP) 1)
Flucytosine (FC)
Voriconazole (VO)
Caspofungin (CS) 1)

35 ± 2°C
24-48h.
Ambient air
48-72h forin bags,
C. neoformans
moist

Candida albicans
C. krusei
C. parapsilosis

90028TM
6258TM
22019TM

Amphotericin B (AP) 1)
Itraconazole (IT)Voriconazole (VO) 1)
Posaconazole (POS) 1)
Caspofungin (CS) 1)

16-72h(Dependent
on genus)

35 ± 2°C
Ambient air
in bags,moist

C. parapsilosis
Aspergillus flavus
A. fumigatus

22019TM
204304TM
204305TM- Once plate inoculated,
re-dip swab and streakagain.

1) In the USA, For Research Use Only (RUO). The contents of this document do not in any way indicate or imply new in vitro diagnostic uses of ETEST®, outside those which are FDA-cleared for certain
antibiotics and organism groups.
2) Worldwide, For Research Use Only (RUO).
3) Example based on CLSI Performance Standards for Antimicrobial Susceptibility Testing supplement M100-S. Please use your own selection of MIC panels.
4) Additional ETEST® information is available at www.biomerieux.com/techlib.
5) For QC of fastidious organisms, please refer to local recommendations and/or CLSI M45-A Methods for Antimicrobial Dilution and Disk Susceptibility Testing of Infrequently Isolated or Fastidious Bacteria.
6) For media available in the bioMérieux range, see pages 10 & 11 (consult www.biomerieux.com/techlib for availability of certificates of compatibility). N.B. bioMérieux media are not sold in all countries. Please consult
your local bioMérieux representative for product availability.
KEY:
BORSA
BSC
ESBL
HLAR
MBL
MRCNS
MRSA
ND
OADC
PAP
VISA/hVISA

Borderline ORSA (non-mec A resistance) due to type A macro-inducible ß-lactamase inhibited by clavulanic acid
Biological Safety Cabinet
Extended Spectrum ß-Lactamase
High-Level Aminoglycoside Resistance
Metallo ß-Lactamase
Methicillin-Resistant Coagulase-Negative Staphylococci (mec A+)
Methicillin-Resistant Staphylococcus aureus (mec A+)
Non-Determinable
Oleic acid, Albumin, Dextrose Complex
Population Analysis Profile
Vancomycin Intermediate/ hetero-Intermediate Staphylococcus aureus
bioMérieux SA

English - 10

ETEST® Application Guide (EAG)

16273D - en - 2019/11

MEDIA AVAILABLE IN THE BIOMERIEUX RANGE
bioMérieux media are not sold in all countries. Please consult your local bioMérieux representative for product availability.
Consult the bioMerieux Technical Library (www.biomerieux.com\techlib) for availability of certificates of compatibility
For non-fastidious bacteria:
 Mueller Hinton E (MHE = Mueller Hinton Agar )Ref. 413822 - 20 plates 90 mm
Ref. 413824 - 100 plates 90 mm
Ref. 413825 - 20 plates 120 x 120 mm

For fastidious bacteria:
EUCAST recommendation:
 Mueller Hinton 2 horse blood NAD agar (MHF)
Ref. 43901 - 20 plates 90 mm
Ref. 43919 - 100 plates 90 mm
Ref. 43904 - 20 plates 120 x 120 mm

 Mueller Hinton Hypersalted (MHA + 2% NaCl)
Ref. AEB521800E - 20 plates 90 mm

CLSI recommendation:
 Mueller Hinton 2 sheep blood agar (MHA + 5% blood)
Ref. 43321 - 20 plates 90 mm
Ref. 43329 - 100 plates 90 mm
Ref. 43324 - 20 plates 120 x 120 mm

 Brain Heart Infusion agar (BHI agar)
Ref. AEB520410 - 20 plates 90 mm
For anaerobes:
 Brucella blood agar (with Vitamin K1 + Hemin) (BBA)
Ref. 411968 - 20 plates 90 mm

For fungi and yeasts:
 RPMI agar
Ref. AEB122180 - 10 plates 90 mm
Ref. AEB122182 - 10 plates 140 mm

bioMérieux SA

English - 11

ETEST® Application Guide (EAG)

16273D - en - 2019/11

SUSPENSION MEDIA AVAILABLE IN THE BIOMERIEUX RANGE
bioMérieux media are not sold in all countries. Please consult your local bioMérieux representative for product availability.
Consult the bioMerieux Technical Library (www.biomerieux.com\techlib) for availability of certificates of compatibility Brain-Heart Infusion broth (BHI broth)Ref. 42081 - 20 x 9 mL
 Mueller Hinton broth (MH broth)Ref. AEB110699 - 100 x 10 mL

 API® NaCl 0.85 % Medium (saline)
Ref. 20070 - 100 x 2mL
Ref. 20040 - 100 x 3mL
Ref. 20230 - 100 x 5mL

 Schaedler Broth + vit. K3
Ref. 42106 - 20 x 13 mL

 Physiological water 0.85 % (saline)
Ref. AEB110391 100 x 5mL
Ref. AEB110389 100 x 9mL
Alternatively,
 Saline Solution
Ref. V1204 - 3 x 500 mL

BIOMERIEUX, the BIOMERIEUX logo, API and ETEST are used, pending and/or registered trademarks belonging to bioMérieux, or one of its subsidiaries, or one of its companies.
CLSI is a trademark belonging to Clinical Laboratory and Standards Institute, Inc.
The ATCC trademark and trade name and any and all ATCC catalog numbers are trademarks of the American Type Culture Collection.
EUCAST stands for European Committee on Antimicrobial Susceptibility Testing. These data have been made available at no cost by EUCAST and can be accessed freely on the EUCAST website: www.eucast.org.
The copyright thereof remains with EUCAST. EUCAST recommendations are frequently updated and the latest versions are available at www.eucast.org.
Any other name or trademark is the property of its respective owner.

bioMérieux SA
376 Chemin de l'Orme69280 Marcy-l'Etoile - France

673 620 399 RCS LYON
Tel. 33 (0)4 78 87 20 00
Fax 33 (0)4 78 87 20 90
www.biomerieux.com